Article Details

(Tideglusib) for Treatment of Congenital Myotonic Dystrophy Type 1 - Markets Insider

Retrieved on: 2021-08-17 06:56:15

Tags for this article:

Click the tags to see associated articles and topics

(Tideglusib) for Treatment of Congenital Myotonic Dystrophy Type 1 - Markets Insider. View article details on hiswai:

Excerpt

The Innovative Passport, a new medicine designation, is the first step in the ILAP process, triggering the MHRA and its partner agencies, including the ...

Article found on: markets.businessinsider.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up